
© 2024 Edison Investment Research
Realtime | Geld | Brief | Zeit |
---|---|---|---|
5,480 | 5,610 | 22:27 | |
5,470 | 5,520 | 22:00 |
Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
18:06 | OSE Immunotherapeutics Presents Preclinical Updates in Immuno-Oncology at AACR Annual Meeting 2025 | ||
14:34 | OSE Immunotherapeutics - Primed for value appreciation | OSE Immunotherapeutics is a clinical-stage immuno-oncology and immuno-inflammation company, with a pipeline spanning all stages of development. The company recently reported its FY24 results, reflecting... ► Artikel lesen | |
26.03. | OSE Immunotherapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update | OSE Immunotherapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update Total income of €83.4 million. Cash level of €64.2 million1 as of December 31, 2024, ensuring financial... ► Artikel lesen | |
12.03. | OSE Immunotherapeutics - Tedopi shows promise in pancreatic cancer | OSE Immunotherapeutics has reported positive top-line data from the investigator-sponsored Phase II trial assessing Tedopi in combination with FOLFIRI (a three-drug chemotherapy regimen made up of folinic... ► Artikel lesen | |
11.03. | OSE Immunotherapeutics and GERCOR Announce Positive Topline Phase 2 Result for Clinical Trial TEDOPaM Evaluating OSE2101 (Tedopi) in Advanced Pancreatic Cancer | OSE Immunotherapeutics and GERCOR Announce Positive Topline Phase 2 Result for Clinical Trial TEDOPaM Evaluating OSE2101 (Tedopi®) in Advanced Pancreatic Cancer Primary endpoint met in randomized... ► Artikel lesen |